Sionna's lead CF drug failed; now it's cutting costs and betting on a backup
Lead cystic fibrosis drug failed its key trial SION-719, Sionna's main drug, did not meaningfully improve CFTR function in a Phase 2a trial — the sweat chloride change was tiny and not statistically significant. The company dropped it as a Trikafta add-on. Since the stock's value rested on this drug, shares collapsed over 90%.
This is the single biggest force behind SION's move and the root cause of everything that followed.
Rival Vertex strengthened as Sionna's threat faded With Sionna's add-on approach shelved, Vertex's dominant cystic fibrosis franchise faces less competition, and Vertex shares hit new highs. That matters for Sionna because the market now sees a harder path to winning any share of the CF market.
It explains the competitive backdrop that makes Sionna's setback worse for its long-term value.
46% workforce cut to save cash after the failure Sionna is cutting nearly half its staff, costing about $6.4 million, to lower spending and stretch its cash into the second half of 2029. It's a sign of retrenchment, but it also buys time to develop the backup program.
It shows the concrete financial and operational fallout of the trial failure, which drives the stock lower.
Backup combo shows promise ahead of 2027 trial Sionna is now focused on SION-451 plus SION-2222, which it will test in the AscenSION Phase 2a trial starting early 2027. New preclinical data showed these NBD1 stabilizers improved CFTR function up to normal levels, offering a possible path forward.
It is the main counterweight — the remaining reason investors see any value in Sionna after the failure.